A citation-based method for searching scientific literature

Matthew J Budoff, John P H Wilding. Int J Clin Pract 2017
Times Cited: 12







List of co-cited articles
176 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
75

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal. Lancet Diabetes Endocrinol 2016
270
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
437
41

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
Silvio E Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, Hans-Jürgen Woerle, Uli C Broedl, Odd Erik Johansen. Diab Vasc Dis Res 2015
245
33

Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
Matthew R Weir, Andrzej Januszewicz, Richard E Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung, Gary Meininger. J Clin Hypertens (Greenwich) 2014
65
33


Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
33

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Karin Rådholm, Gemma Figtree, Vlado Perkovic, Scott D Solomon, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Terrance D Barrett, Wayne Shaw, Mehul Desai,[...]. Circulation 2018
205
33

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
33


Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
Huilin Tang, Xi Zhang, Jingjing Zhang, Yufeng Li, Liana C Del Gobbo, Suodi Zhai, Yiqing Song. Diabetologia 2016
49
25

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
551
25


Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Mehul Desai, Wayne Shaw, Gordon Law, Marc K Walton, Norm Rosenthal,[...]. Diabetes Obes Metab 2017
68
25

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
S Sha, D Polidori, T Heise, J Natarajan, K Farrell, S-S Wang, D Sica, P Rothenberg, L Plum-Mörschel. Diabetes Obes Metab 2014
137
25

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
B Bode, K Stenlöf, S Harris, D Sullivan, A Fung, K Usiskin, G Meininger. Diabetes Obes Metab 2015
142
25

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
488
25

Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Keith Usiskin, Irina Kline, Albert Fung, Cristiana Mayer, Gary Meininger. Postgrad Med 2014
74
25

Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
Rong Qiu, Dainius Balis, John Xie, Michael J Davies, Mehul Desai, Gary Meininger. Curr Med Res Opin 2017
20
25

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
215
25



Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Mikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Marit E Jørgensen, Eric T Wittbrodt,[...]. Diabetes Obes Metab 2018
46
25

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
David Fitchett, Javed Butler, Philippe van de Borne, Bernard Zinman, John M Lachin, Christoph Wanner, Hans J Woerle, Stefan Hantel, Jyothis T George, Odd Erik Johansen,[...]. Eur Heart J 2018
140
25

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
473
25

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
Christian Sonesson, Peter A Johansson, Eva Johnsson, Ingrid Gause-Nilsson. Cardiovasc Diabetol 2016
113
25

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
392
25

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
216
25

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Subodh Verma, C David Mazer, Mohammed Al-Omran, Silvio E Inzucchi, David Fitchett, Uwe Hehnke, Jyothis T George, Bernard Zinman. Circulation 2018
84
25

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell, Julie A Lovshin, David Z I Cherney. Circulation 2017
190
25

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
291
25

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
Javed Butler, Carine E Hamo, Gerasimos Filippatos, Stuart J Pocock, Richard A Bernstein, Martina Brueckmann, Alfred K Cheung, Jyothis T George, Jennifer B Green, James L Januzzi,[...]. Eur J Heart Fail 2017
98
25

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
257
25

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar, James McLaren, Søren L Kristensen, David Preiss, John J McMurray. Diabetologia 2016
171
25


Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, David Fitchett, Sven Kohler, Michaela Mattheus, Hans J Woerle, Uli C Broedl, Odd Erik Johansen,[...]. Stroke 2017
72
25


Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
130
25

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
452
25

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
Hiroyuki Tanaka, Kazuhiko Takano, Hiroaki Iijima, Hajime Kubo, Nobuko Maruyama, Toshio Hashimoto, Kenji Arakawa, Masanori Togo, Nobuya Inagaki, Kohei Kaku. Adv Ther 2017
60
25

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Gian Paolo Fadini, Benedetta Maria Bonora, Giancarlo Zatti, Nicola Vitturi, Elisabetta Iori, Maria Cristina Marescotti, Mattia Albiero, Angelo Avogaro. Cardiovasc Diabetol 2017
41
25

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
201
25

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
100
25

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Naveed Sattar, Björn Eliasson, Ann-Marie Svensson, Björn Zethelius, Mervete Miftaraj, Darren K McGuire, Annika Rosengren,[...]. N Engl J Med 2018
385
25


Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li,[...]. Circulation 2018
225
25

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
Raymond V Oliva, George L Bakris. J Am Soc Hypertens 2014
137
25

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
202
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.